MedTrace Logo

Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)

NCT03648489 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 134

Last updated 2024-09-20

No results posted yet for this study

Summary

DICE is a randomised study recruiting 126 women over 3 years from hospitals in the UK and Germany. Eligible patients will have tissue based diagnosis of advanced/recurrent ovarian cancer (clear cell, endometrioid or high grade serous or carcinosarcoma), have had chemotherapy before, and be platinum-resistant (the cancer has returned/grown significantly during or within 6 months of platinum-containing chemotherapy).

Conditions

Interventions

DRUG

Paclitaxel

Please refer to arm/group description

DRUG

TAK228

Please refer to arm/group description

Sponsors & Collaborators

  • Takeda Pharmaceuticals International, Inc.

    collaborator INDUSTRY

  • North Eastern German Society of Gynaecological Oncology

    collaborator OTHER

  • Imperial College London

    lead OTHER

Principal Investigators

  • Jonathan Krell · Imperial College London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-21
Primary Completion
2023-11-30
Completion
2023-11-30

Countries

  • Germany
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03648489 on ClinicalTrials.gov